[Lieyun Network (WeChat:ilieyun
) Beijing] February 16th report
On February 16, SceneRay announced the successful completion of a 300 million RMB D+ round of financing, jointly led by HongShan and GL Ventures.
Discussing the investment logic, the head of GL Ventures' project stated: "The field of brain science holds immense market prospects and potential. After years of development, Sceneray has built a strong foundation on rigorous medical scientific research, adopting innovative technology as its R&D philosophy. With keen insight into clinical needs, the company has successfully implemented deep brain stimulation and brain-computer interface applications. Its First-in-Class innovative products have introduced breakthrough therapies for various diseases. GL Ventures continues to be optimistic about the brain science industry and the company's future. We will keep supporting the company in reaching new heights, bringing more benefits to patients, and showcasing the extraordinary strength of Chinese innovation on the international stage."
Dr. Chen Xuanze, Vice President of HongShan, stated: "The industrial development of brain science is one of our key focus areas, and HongShan has also established a brain science incubation center to support the industrialization of brain science in China. The core team of Sceneray consists of leading experts in deep brain stimulation systems, with extensive experience. They have developed key technologies in brain-computer interface neuromodulation chips, dual-target electrical stimulation, remote control, and AI-assisted fields, truly realizing the transformation from cutting-edge technology to industrial application. We are delighted to partner with Sceneray to help extend the application of deep brain stimulation products to more indications, benefiting more patients."
It is reported that Sceneray is an innovative high-tech medical device enterprise that integrates research and development, production, and sales. For many years, it has been deeply engaged in the field of deep brain stimulation ("DBS") therapy, while also leading the frontier exploration of invasive brain-computer interfaces for medical use. The company has gathered more than 200 talents and adheres to independent research and development, global innovation, and self-owned production.
Currently, through continuous iteration of its deep brain stimulation devices, Sceneray has carved out a differentiated development path in the field of brain electrical stimulation that suits its own strengths. Relying on its self-developed chip, Sceneray's rechargeable deep brain stimulation device, which is already on the market, has achieved breakthroughs and expansions compared to similar products globally, featuring the smallest size, the most functions, lower power consumption, the longest lifespan, and a wider range of therapeutic applications.
Not only that, but Sceneray has also entered the "uncharted territory" of brain disease treatment, being the first to propose a dual-target stimulation therapy. They have developed a brain-computer interface dual-target deep brain stimulator for treating refractory obsessive-compulsive disorder, drug addiction, and alcohol addiction, achieving breakthrough therapeutic effects.
Mr. Ning Yihua, founder and chairman of Sceneray, stated: "Healthcare is an industry driven by rigid demand, and it also requires patient and persistent efforts. Research in the field of brain science presents even more challenges. Looking back over more than a decade of diligent work, our company has achieved several breakthroughs at the forefront of neuroscience through independent research and development. The brain pacemaker, which incorporates multiple innovative technologies from Sceneray, has gained unanimous recognition within the industry and is leading globally in the development of various indications. Finally, we sincerely thank both new and existing shareholders for their support and trust. Sceneray always keeps its mission in mind, striving to enable more patients to benefit from high-tech medical treatments, and is committed to becoming a world-leading enterprise."